Solid Tumor
Conditions
Keywords
MicroRNA, Solid Tumor, Lipid-nanoparticle
Brief summary
This is a 2 part, multi-center, open-label, First-in-Human clinical study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of INT-1B3 in the treatment of patients with advanced solid tumors.
Detailed description
The investigational medicinal product INT-1B3 is a lipid nanoparticle formulated microRNA (miR-193a-3p) mimic destined for therapeutic intervention in oncology. Preclinical work showed that INT-1B3 has a multi-target mechanism of action with an anti-proliferative, anti-metastatic, anti-migration, cell cycle disruption, induction of apoptosis effect and modulation on the tumor microenvironment leading to significant induction of T cell-mediated immune response. The first part of the study (Phase I) is a dose-escalation phase to determine the maximal tolerated dose and the recommended Phase 2 dose, as well as the safety profile of INT-1B3 in patients with advanced malignancies.The subsequent expansion phase of the study (Phase Ib) will further explore safety, pharmacokinetics, pharmacodynamic responses, and antitumor activity of INT-1B3 in patients with selected cancer types treated at the recommended phase 2 dose.
Interventions
DRUGINT-1B3
60-min i.v. infusions twice per week in 21-day cycles
Sponsors
InteRNA
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient provided a signed written informed consent before any screening procedure 2. Patient is male or female, ≥18 years of age (adult patients) 3. Patient with histologically or cytologically confirmed advanced and/or metastatic solid tumor, with progressive disease at baseline, for whom no standard treatment is available or who have declined standard therapy 4. Patient with evaluable disease per RECIST v1.1, iRECIST 5. Patient with a predicted life expectancy of \> 12 weeks 6. Patient with Eastern Cooperative Oncology Group performance status of grade 0 - 1 7. Patient with hemoglobin ≥ 9.0 g/dL, platelet count ≥ 75×109/L, and absolute neutrophil count ≥ 1.0×109/L 8. Patient with adequate renal function 9. Patient with adequate liver function 10. Patient with adequate coagulation tests 11. Female patient of childbearing potential and males should use effective contraception 12. Patient is able and willing to comply with the protocol and the restrictions and assessments therein
Exclusion criteria
1. Patients on any other anti-cancer therapy, unless at least 4 weeks (or 5 half-lives, whichever is shorter), have elapsed since the last dose before the first administration of INT-1B3. At least 2 weeks should have elapsed since receiving non-palliative radiotherapy. 2. Patient with known central nervous system (CNS) metastases, unless previously treated and well-controlled for at least 1 month (defined as clinically stable, no edema, no steroids and stable in 2 scans at least 4 weeks apart) 3. Patient with concomitant second malignancies unless curatively treated at least 2 years before study entry with no additional therapy required or anticipated to be required during the study period 4. Patient with major surgery within 5 weeks before initiating treatment or with minor surgical procedure within 7 days before initiating treatment 5. Patient with active autoimmune disease or persistent immune-mediated toxicity caused by immune checkpoint inhibitor therapy of Grade ≥ 2, except for residual endocrinopathy adequately substituted, vitiligo, Type 1 diabetes mellitus or psoriasis not requiring systemic therapy (\>10mg prednisone equivalent) 6. Patient with toxicity (except for alopecia) related to prior anti-cancer therapy and/or surgery, unless the toxicity is either resolved, returned to baseline or grade 1 7. Patient with any active neuropathy \> Grade 2 (National Cancer Institute Common Terminology Criteria for Adverse Events v5.0) 8. Patient with any condition requiring concurrent use of systemic immunosuppressants or corticosteroids at a daily dose \> 10 mg prednisone equivalent or other immunosuppressive medications within 14 days of study medication administration 9. Patient with evidence of active infection that requires systemic antibacterial, antiviral, or antifungal therapy ≤ 7 days before the first dose of study medication 10. Patient with uncontrolled or significant cardiovascular disease 11. Patient with known active or chronic hepatitis B or C (unless treated with no detectable virus) 12. Patient with known history of exposure to human immunodeficiency virus (HIV) 13. Patient with any known or underlying medical, psychiatric condition, and/or social situations that, in the opinion of the investigator, would limit compliance with study requirements 14. Patient with history of allergy to the study medication or any of its excipients 15. Patient that received packed red blood cells or platelet transfusion within 2 weeks of the first dose of study medication 16. Female patient: pregnant or breastfeeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence and severity of treatment-related adverse events and serious adverse events | Up to 24 months | Incidence and severity of adverse events, serious adverse events, according to NCI-CTCAE criteria v 5.0, incidence of dose limiting toxicities (DLTs), adverse events leading to discontinuation and deaths |
| Recommended Phase 2 Dose of INT-1B3 | Up to 24 months | Based on dose-limiting toxicities, the maximal tolerated dose and all other available safety, pharmacokinetic/pharmacodynamic data as assessed by the cohort review committee |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time of maximum plasma concentration | Up to 24 months | Time to reach highest observed plasma concentration of INT-1B3 |
| Area under the curve | Up to 24 months | Area under the plasma concentration time curve of INT-1B3 |
| Objective response rate of INT-1B3 | Up to 24 months | Objective response rate according to standard criteria by RECIST1.1 |
| Half-life | Up to 24 months | Plasma concentration half-life of INT-1B3 |
| Maximum plasma concentration | Up to 24 months | Highest observed plasma concentration of INT-1B3 |
Countries
Belgium, Netherlands
Outcome results
None listed